These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12015873)

  • 1. New dosing regimen approved.
    AIDS Patient Care STDS; 2002 Apr; 16(4):190. PubMed ID: 12015873
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS Treat News; 2002 Mar; (378):6-7. PubMed ID: 11965920
    [No Abstract]   [Full Text] [Related]  

  • 3. Lower dose of ritonavir approved for use with fosamprenavir.
    Sax PE
    AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
    [No Abstract]   [Full Text] [Related]  

  • 4. [Individualized therapy with fosamprenavir/r. A PI suitable in liver problems].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():60-1. PubMed ID: 19031566
    [No Abstract]   [Full Text] [Related]  

  • 5. [Potent new protease inhibitor. Boostered protease inhibitors--a separate class of drugs].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():40-1. PubMed ID: 15011585
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug interactions. Amprenavir with low-dose ritonavir.
    TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
    [No Abstract]   [Full Text] [Related]  

  • 7. New anti-HIV drugs in development.
    Proj Inf Perspect; 1999 Sep; (28):4-8. PubMed ID: 11367365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III results presented on amprenavir triple combination.
    AIDS Patient Care STDS; 1998 Dec; 12(12):941-2. PubMed ID: 11362070
    [No Abstract]   [Full Text] [Related]  

  • 9. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
    Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 11. Fosamprenavir calcium plus ritonavir for HIV infection.
    Torres HA; Arduino RC
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amprenavir approved.
    AIDS Patient Care STDS; 1999 Jul; 13(7):438. PubMed ID: 10870601
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combo approved for HIV treatment.
    Nurse Pract; 2004 Mar; 29(3):40. PubMed ID: 15052701
    [No Abstract]   [Full Text] [Related]  

  • 15. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
    AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ritonavir/indinavir combination study shows promising dosing results.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146-7. PubMed ID: 11361915
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
    J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boosted saquinavir approved.
    AIDS Patient Care STDS; 2004 Mar; 18(3):183. PubMed ID: 15112642
    [No Abstract]   [Full Text] [Related]  

  • 19. Agenerase approved by FDA.
    Gaylord G
    Posit Living; 1999 May; 8(4):6. PubMed ID: 12492061
    [No Abstract]   [Full Text] [Related]  

  • 20. Raising levels of amprenavi.
    AIDS Patient Care STDS; 2000 Nov; 14(11):618. PubMed ID: 11155905
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.